{
    "title": "110_hr4083",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Non-Prescription Drug Modernization \nAct of 2007''.\n\nSEC. 2. AMENDING OR REPEALING MONOGRAPHS.\n\n    Subchapter E of chapter V of the Federal Food, Drug, and Cosmetic \nAct (21 U.S.C. 360bbb et seq.) is amended by adding at the end the \nfollowing:\n\n``SEC. 568. AMENDING OR REPEALING MONOGRAPHS.\n\n    ``(a) Good Cause.--In applying section 553 of title 5, United \nStates Code, to any amendment to or repeal of a monograph established \npursuant to section 330.10 of title 21, Code of Federal Regulations (or \nany successor regulation), good cause (as such term is used in \nsubsections (b) and (d) of such section 553) is deemed to exist, and \nnotice and public procedure are deemed to be unnecessary (as such term \nis used in subsection (b) of such section 553), for purposes of making \nsuch amendment or repeal if--\n            ``(1) there is a finding--\n                    ``(A) by the Secretary that the category of drugs \n                or the specific drug involved is associated with a \n                significant risk; or\n                    ``(B) by the Secretary, after holding a meeting of \n                an advisory committee of the Food and Drug \n                Administration to evaluate the category of drugs or the \n                specific drug involved, that such category of drugs or \n                specific drug lacks evidence of effectiveness; and\n            ``(2) such amendment or repeal is based, in whole or in \n        part, on such finding.\n    ``(b) Subsequent Comment Period.--After the amendment or repeal of \na monograph in accordance with subsection (a), the Secretary may \nprovide a period for public comments on the amendment or repeal and may \nmake additional changes with respect to the monograph to reflect \ncomments received, if determined appropriate by the Secretary.''.\n\nSEC. 3. EXPANSION OF FDA'S AUTHORITY TO REGULATE DRUG ADVERTISING.\n\n    (a) In General.--The Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 301 et seq.) is amended--\n            (1) in section 303(g)(1), by striking ``With respect to'' \n        and all that follows through ``section 351 of the Public Health \n        Service Act,'' and inserting ``With respect to a person who is \n        a holder of an approved application under section 505 or under \n        section 351 of the Public Health Service Act, or a person who \n        is the manufacturer of a drug marketed pursuant to a monograph \n        established pursuant to section 330.10 of title 21, Code of \n        Federal Regulations (or any successor regulation),''; and\n            (2) in section 502(n)--\n                    (A) by striking the term ``prescription drug'' each \n                place such term appears and inserting ``drug''; and\n                    (B) by striking ``subject to section 503(b)(1)''.\n    (b) Regulations.--The Commissioner of Food and Drugs shall \npromulgate such revisions to the regulations under section 502(n) of \nthe Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(n)) as may be \nnecessary to carry out the amendments made by subsection (a).\n    (c) Transitional Provisions.--\n            (1) False or misleading advertisements.--During the period \n        beginning on the date of the enactment of this Act and ending \n        on the effective date of the regulations required by subsection \n        (b), a drug other than a prescription drug is deemed to be \n        misbranded under section 502(n) of the Federal Food, Drug, and \n        Cosmetic Act (21 U.S.C. 352(n)) if any advertisement or other \n        descriptive printed matter issued or caused to be issued by the \n        manufacturer, packer, or distributer with respect to that drug \n        is false or misleading.\n            (2) Definitions.--The terms used in this subsection have \n        the meanings applicable to those terms in section 502(n) of the \n        Federal Food, Drug, and Cosmetic Act (21 U.S.C. 352(n)).\n\nSEC. 4. IDENTIFICATION AND REPORT ON MONOGRAPHS.\n\n    (a) Identification.--\n            (1) In general.--The Commissioner of Food and Drugs (in \n        this section referred to as the ``Commissioner'') shall \n        identify each monograph established pursuant to section 330.10 \n        of title 21, Code of Federal Regulations, that may require \n        further review to determine whether the monograph is in need of \n        amendment or repeal.\n            (2) Public comments.--To assist in the identification of \n        such monographs, the Commissioner shall give interested \n        persons, including medical societies and other entities with \n        expertise on drugs, an opportunity to submit comments.\n    (b) Report.--Not later than 2 years after the date of the enactment \nof this Act, the Commissioner shall submit a report to the Congress \nidentifying any monographs that, as determined by the Commissioner, may \nrequire further review to determine whether such monographs are in need \nof amendment or repeal. Such report shall include--\n            (1) an assessment of the resources necessary to conduct \n        such review and make such amendments or repeals;\n            (2) a summary of the comments received under subsection \n        (a)(2); and\n            (3) a listing of the monographs that, as recommended in \n        such comments, are in need of amendment or repeal and the basis \n        for such recommendations.\n\nSEC. 5. AUTHORIZATION OF APPROPRIATIONS.\n\n    To carry out this Act and the amendments made by this Act, there \nare authorized to be appropriated such sums as may be necessary."
}